97 related articles for article (PubMed ID: 19683286)
1. Pathological effects of prostate cancer correlate with neuroendocrine differentiation and PTEN expression after bicalutamide monotherapy.
Ham WS; Cho NH; Kim WT; Ju HJ; Lee JS; Choi YD
J Urol; 2009 Oct; 182(4):1378-84. PubMed ID: 19683286
[TBL] [Abstract][Full Text] [Related]
2. Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer.
Festuccia C; Gravina GL; Muzi P; Pomante R; Ventura L; Vessella RL; Vicentini C; Bologna M
Endocr Relat Cancer; 2007 Sep; 14(3):601-11. PubMed ID: 17914091
[TBL] [Abstract][Full Text] [Related]
3. Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer.
Gravina GL; Festuccia C; Galatioto GP; Muzi P; Angelucci A; Ronchi P; Costa AM; Bologna M; Vicentini C
Urology; 2007 Oct; 70(4):728-33. PubMed ID: 17991545
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
5. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
[TBL] [Abstract][Full Text] [Related]
6. Microtubule-associated protein tau (MAPT) promotes bicalutamide resistance and is associated with survival in prostate cancer.
Sekino Y; Han X; Babasaki T; Goto K; Inoue S; Hayashi T; Teishima J; Shiota M; Takeshima Y; Yasui W; Matsubara A
Urol Oncol; 2020 Oct; 38(10):795.e1-795.e8. PubMed ID: 32430253
[TBL] [Abstract][Full Text] [Related]
7. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
8. Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.
Kitagawa Y; Hinotsu S; Shigehara K; Nakashima K; Kawaguchi S; Yaegashi H; Mizokami A; Akaza H; Namiki M
Int J Urol; 2013 Jul; 20(7):708-14. PubMed ID: 23216462
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant hormonal treatment - the bicalutamide early prostate cancer program.
Wirth MP; Hakenberg OW; Froehner M
Front Radiat Ther Oncol; 2008; 41():39-48. PubMed ID: 18544984
[TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.
Boutin B; Tajeddine N; Vandersmissen P; Zanou N; Van Schoor M; Mondin L; Courtoy PJ; Tombal B; Gailly P
Prostate; 2013 Jul; 73(10):1090-102. PubMed ID: 23532738
[TBL] [Abstract][Full Text] [Related]
11. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
Lodde M; Lacombe L; Fradet Y
Urology; 2010 Nov; 76(5):1189-93. PubMed ID: 20303155
[TBL] [Abstract][Full Text] [Related]
12. Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program.
Iversen P; Wirth MP; See WA; McLeod DG; Klimberg I; Gleason D; Chodak G; Montie J; Tyrrell C; Wallace DM; Delaere KP; Lundmo P; Tammela TL; Johansson JE; Morris T; Carroll K;
Urology; 2004 May; 63(5):928-33. PubMed ID: 15134983
[TBL] [Abstract][Full Text] [Related]
13. Up-Regulation of LAT1 during Antiandrogen Therapy Contributes to Progression in Prostate Cancer Cells.
Xu M; Sakamoto S; Matsushima J; Kimura T; Ueda T; Mizokami A; Kanai Y; Ichikawa T
J Urol; 2016 May; 195(5):1588-1597. PubMed ID: 26682754
[TBL] [Abstract][Full Text] [Related]
14. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.
Iversen P; Tyrrell CJ; Kaisary AV; Anderson JB; Van Poppel H; Tammela TL; Chamberlain M; Carroll K; Melezinek I
J Urol; 2000 Nov; 164(5):1579-82. PubMed ID: 11025708
[TBL] [Abstract][Full Text] [Related]
15. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer.
Iversen P; Roder MA
Expert Rev Anticancer Ther; 2008 Mar; 8(3):361-9. PubMed ID: 18366284
[TBL] [Abstract][Full Text] [Related]
16. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years.
Iversen P; McLeod DG; See WA; Morris T; Armstrong J; Wirth MP;
BJU Int; 2010 Apr; 105(8):1074-81. PubMed ID: 22129214
[TBL] [Abstract][Full Text] [Related]
17. Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health-related quality of life benefits for osteoporotic men with prostate cancer.
Wadhwa VK; Weston R; Parr NJ
BJU Int; 2011 Jun; 107(12):1923-9. PubMed ID: 20950306
[TBL] [Abstract][Full Text] [Related]
18. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.
McLeod DG; Iversen P; See WA; Morris T; Armstrong J; Wirth MP;
BJU Int; 2006 Feb; 97(2):247-54. PubMed ID: 16430622
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma.
Festuccia C; Gravina GL; Muzi P; Pomante R; Ventura L; Ricevuto E; Vicentini C; Bologna M
Prostate; 2007 Sep; 67(12):1255-64. PubMed ID: 17596848
[TBL] [Abstract][Full Text] [Related]
20. Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma.
Zhigang Z; Wenlu S
Prostate; 2005 Dec; 65(4):299-305. PubMed ID: 16015594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
